What is Corvus Pharmaceuticals Inc (CRVS) stock price today?

Corvus Pharmaceuticals Inc (CRVS) currently trades at $15.19 per share. The stock has a market capitalization of $1.35B and a P/E ratio of —x.

Is CRVS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Corvus Pharmaceuticals Inc has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -9.26.

Is Corvus Pharmaceuticals Inc financially healthy?

Corvus Pharmaceuticals Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -9.26 places it in the distress.

CRVS

Corvus Pharmaceuticals Inc

NASDAQ: CRVS · HEALTHCARE · BIOTECHNOLOGY

$15.19

+5.34% today

Updated 2026-04-30

Market cap

$1.35B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.53

Dividend yield

—

52W range

$3 – $27

Volume

1.3M

Market cap

$1.35B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.53

Dividend yield

—

52W range

$3 – $27

Volume

1.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-9.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$35.86

+136.08%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -9.26 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-9.22M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-41.31M	$-27.03M	$-62.29M	$-15.28M	$-12.32M
EPS	—	—	—	—	$-0.53
Free cash flow	$-27.29M	$-23.97M	$-25.42M	$-32.97M	$-9.22M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CRVS	$1.35B	22	4.3	3.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Corvus Pharmaceuticals Inc trades at $15.19. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -9.26, it sits in the distress.

Frequently asked questions

What is Corvus Pharmaceuticals Inc's stock price?

Corvus Pharmaceuticals Inc (CRVS) trades at $15.19.

Is Corvus Pharmaceuticals Inc overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Corvus Pharmaceuticals Inc (CRVS)?

The analyst target price is $35.86, representing +136.1% upside from the current price of $15.19.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-9.26 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.corvuspharma.com

Quick metrics

P/S ratio—

ROE-32.60%

Beta0.97

50D MA$15.93

200D MA$10.23

Shares out0.08B

Float0.07B

Short ratio—

Avg volume1.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CRVS vs LLY →CRVS vs JNJ →CRVS vs ABBV →Stock screener →